Please login to the form below

Not currently logged in
Email:
Password:

schizophrenia

This page shows the latest schizophrenia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

schizophrenia. The CHMP also recommended Sandoz’s biosimilar of AbbVie’s blockbuster inflammation treatment Humira.

Latest news

More from news
Approximately 26 fully matching, plus 256 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    According to a systematic review of 39 studies, published in Clinical Psychology in 2002, a mean rate of medication non-adherence in schizophrenia sufferers is 41%, one of the highest of ... Furthermore, given the serious negative effects of

  • Tackling the challenge of non-adherence Tackling the challenge of non-adherence

    Rates of adherence are especially low among patients with chronic conditions such as COPD (33%), schizophrenia (52%) and asthma (67%). ... 80% in just five disease areas - asthma, type 2 diabetes, coronary heart disease, hypertension and schizophrenia -

  • Digital disruption Digital disruption

    Starting with projects in schizophrenia and Parkinson’s disease, Lundbeck and IBM will also work together to identify potential new drug targets and alternative indications.

  • Pharma deals in February 2015 Pharma deals in February 2015

    in-house clinical and preclinical pipeline targeting serious diseases with blockbuster potential eg Alzheimer's disease, ADHD, metabolic disease, schizophrenia, migraine.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics